Lantus and Skin hypertrophy - a phase IV clinical study of FDA data
Skin hypertrophy is found among people who take Lantus, especially for people who are male, 50-59 old.
The phase IV clinical study analyzes which people take Lantus and have Skin hypertrophy. It is created by eHealthMe based on reports of 175,171 people who have side effects when taking Lantus from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
175,171 people reported to have side effects when taking Lantus.
Among them, 133 people (0.08%) have Skin hypertrophy.
What is Lantus?
Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 176,435 Lantus users for its effectiveness, alternative drugs and more.
What is Skin hypertrophy?
Skin hypertrophy (skin cells enlarges) is found to be associated with 1,051 drugs and 509 conditions by eHealthMe.
Number of Lantus and Skin hypertrophy reports submitted per year:
Gender of people who have Skin hypertrophy when taking Lantus*:
Age of people who have Skin hypertrophy when taking Lantus *:
Common drugs people take besides Lantus *:
Common side effects people have besides Skin hypertrophy *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Lantus and have Skin hypertrophy?Check whether Skin hypertrophy is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Skin hypertrophy and when was it recovered:
Expand to all the drugs that have ingredients of insulin glargine recombinant:
Alternative drugs to, pros and cons of Lantus:
- Lantus (176,435 reports)
Common Lantus side effects:
- Drug ineffective: 7,911 reports
- Hypoglycemia (low blood sugar): 7,019 reports
- Fatigue (feeling of tiredness): 6,249 reports
- Weight decreased: 5,887 reports
- Weakness: 5,796 reports
- Diarrhea: 5,760 reports
- Breathing difficulty: 5,735 reports
Browse all side effects of Lantus:a b c d e f g h i j k l m n o p q r s t u v w x y z
Skin hypertrophy treatments and more:
- Skin hypertrophy (3,618 reports)
COVID vaccines that are related to Skin hypertrophy:
- Skin hypertrophy in Moderna COVID Vaccine
- Skin hypertrophy in Pfizer BioNTech Covid Vaccine
- Skin hypertrophy in Johnson and Johnson Covid Vaccine
Common drugs associated with Skin hypertrophy:
- Magnevist: 1,066 reports
- Omniscan: 889 reports
- Optimark: 676 reports
- Multihance: 605 reports
- Prohance: 570 reports
- Renagel: 512 reports
- Prednisone: 462 reports
- Coumadin: 393 reports
- Aspirin: 364 reports
- Phoslo: 346 reports
All the drugs that are associated with Skin hypertrophy:
- Skin hypertrophy (1,051 drugs)
Common conditions associated with Skin hypertrophy:
- Arteriogram: 388 reports
- High blood pressure: 227 reports
- Pain: 175 reports
- Rheumatoid arthritis: 172 reports
- Diabetes: 111 reports
All the conditions that are associated with Skin hypertrophy:
- Skin hypertrophy (509 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Oramorph Sr vs. Flector - now
- Duragesic-25 vs. Flexeril - now
- Dilaudid-Hp vs. Darvocet-N 100 - a second ago
- Cenestin and Nasal Congestion - 4 seconds ago
- Eplerenone and Weight Abnormal - 5 seconds ago
- Olanzapine and Tracheitis - 5 seconds ago
- Acetaminophen And Codeine Phosphate and Olive drug interaction - 6 seconds ago
- Uroxatral and Deep Venous Thrombosis - 7 seconds ago
- Valsartan And Hydrochlorothiazide vs. Atacand Hct - 8 seconds ago
- Pioglitazone vs. Altace - 9 seconds ago